Bosello S, De santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferracciolo G: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow up open-label trial. Arthritis Res Ther. 2010, 12: R54-10.1186/ar2965.
Article
PubMed Central
PubMed
Google Scholar
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel P, Simms RW: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009, 60: 578-583. 10.1002/art.24249.
Article
PubMed Central
PubMed
Google Scholar
Daoussis D, Liossis SC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karametsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010, 49: 271-280. 10.1093/rheumatology/kep093.
Article
PubMed Central
CAS
PubMed
Google Scholar
Smith V, Van Praet JT, Vandooren B, Cruyssen Van der B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010, 69: 193-197. 10.1136/ard.2008.095463.
Article
CAS
PubMed
Google Scholar
Wollheim FA: Is rituximab a potential new therapy in systemic sclerosis? New evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J Clin Rheumatol. 2004, 10: 155-10.1097/01.rhu.0000129090.86550.1e.
Article
PubMed
Google Scholar
Kraaij MD, van Laar JM: The role of B cells in systemic sclerosis. Biologics. 2008, 2: 389-395.
PubMed Central
CAS
PubMed
Google Scholar
Daoussis D, Liossis SC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP: Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum.
McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S: Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology. 2008, 47: 552-553. 10.1093/rheumatology/kem357.
Article
CAS
PubMed
Google Scholar
Yoo WH: Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int. 2010,
Google Scholar
Fabri M, Hunzelmann N, Krieg T: Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol. 2008, 58 (5 Suppl 1): S127-128. 10.1016/j.jaad.2007.06.010.
Article
PubMed
Google Scholar